In patients with IBD, it was found that gut microbial levels lack in diversity. After receiving infliximab treatment, CD patients restored their microbial diversity and increased their Clostridiales levels. Clostridiales reduced proinflammatory bacteria, produced short-chain fatty acids, and induced an immune response.
A noninvasive evaluation determining the severity of inflammatory bowel disease (IBD) and the treatment efficacy of infliximab is made possible by locating universal biomarkers in human fecal microbiota, according to a study published by the American Society for Microbiology's mSystems.
An increase in industrialization across the world has caused an increase of IBD among populations in less developed regions; ulcerative colitis (UC) and Crohn disease (CD) are the 2 main clinical types of IBD, with global incidence of these diseases on the rise.
The etiology of these conditions is not well understood; however, past research has suggested that an imbalance of gut microbiota may be the main cause of IBD. In the literature, IBD patients when compared to healthy individuals have a reduced biodiversity, a decreased abundance of several taxa in the Firmicutes phylum, and an increased abundance of Gammaproteobacteria throughout the digestive system.
In the study, researchers profiled the fecal microbiota from a cohort of Chinese patients with IBD, then compared the results to 2 western IBD cohorts by using bar-coded 165 rRNA amplicon sequencing. IBD patients included in the study were also compared to healthy western and Chinese individuals. This was a multicenter association study in which over 1000 treatment-naïve patients participated.
The goals of the study were to locate the microbiota patterns in Chinese IBD patients with different disease activities, discover different gut microbiota patterns across ethnicities and geographic locations, and to recognize any universal biomarkers across the IBD cohorts that could indicate and predict disease progression and infliximab treatment efficacy.
1,376,142 rRNA gene sequences were taken from 196 samples. A microbial imbalance of gut microbiota patterns was found in Chinese IBD patients. In addition, researchers recognized that the sequencing of gut microbiota in Chinese IBD patients was similar to those of the western cohorts. Researchers also saw gut microbiota being restored during disease remission while certain microbes, like Clostridiales, displayed the body’s response to infliximab treatment of CD.
In patients with IBD, it was found that gut microbial levels lack in diversity. After receiving infliximab treatment, CD patients restored their microbial diversity and increased their Clostridiales levels. Clostridiales reduced proinflammatory bacteria, produced short-chain fatty acids, and induced an immune response.
“Our results reinforce the idea that the gut microbiota contains promising biomarkers for the noninvasive evaluation of IBD activity and assessment of therapeutic responses,” the authors concluded. “The identification of [a] disease-activity associated microbiome is a step toward establishing a set of microbiota-based biomarkers for the assessment of treatment and progression of inflammatory bowel disease.”
Reference
Zhou Y, Xu ZZ, He Y, et al. Gut microbiota offers universal biomarkers across ethnicity in inflammatory bowel disease diagnosis and infliximab response prediction. mSystems. 2018;3(1):e00188-17. doi: 10.1128/mSystems.00188-17.
Review: Product Attributes Relevant to Injection-Site Pain, Adalimumab Treatment
May 4th 2024A review article summarizes the product attributes of reference and biosimilar adalimumab products, such as formulation with or without citrate, delivery volume, and needle gauge, relevant to patients’ experience of injection-site pain.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition
February 4th 2024On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.